[The clinical significance of tissue polypeptide antigen (TPA) in the patients with gynecologic tumor].
In order to estimate the clinical significance of tissue polypeptide antigen (TPA), TPA was measured by radioimmunoassay in sera from patients with various gynecological tumors. They were 40 uterine myomas, 94 cervical cancers, 21 endometrial cancers, 3 vulval cancers, 51 benign ovarian tumors and 78 malignant ovarian tumors including 18 low potential malignant tumors (LPM). The mean TPA values in patients with benign as well as malignant tumors were significantly higher than that of 97 healthy volunteers (68 +/- 17 U/l; Upper limit; 107 U/l). Among the cervical cancer patients, serum TPA level and positive ratio became higher as the disease progressed. In the advanced cases, the mean serum TPA value and positive ratio were 149 +/- 64 U/l and 75%, respectively. The mean TPA value in the endometrial cancer patients was significantly higher than that of myoma patients. Among the patients with ovarian tumor, serum TPA was elevated in 14% of benign cases, 28% of LPM cases, 47% of stage I cases and 82% of the advanced cases. Serum TPA values varied directly with the stage and malignancy of disease. The present study revealed that TPA is a useful markers in the diagnosis of gynecological tumors, especially for ovarian cancers.
D000230:Adenocarcinoma / Q000276:immunology; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D003884:Dermoid Cyst / Q000276:immunology; D005260:Female; D005833:Genital Neoplasms, Female / Q000276:immunology*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000276:immunology; D010455:Peptides / Q000032:analysis*; D011863:Radioimmunoassay; D019396:Tissue Polypeptide Antigen
D010455:Peptides; D019396:Tissue Polypeptide Antigen